01 Multiplex Immunoassays Combining More Protein Markers in a Single Run Clinical laboratories increasingly need broader biomarker information from limited sample volumes, which makes single-analyte testing less efficient for complex diagnostic workups. Multiplex immunoassay platforms are therefore combining several antibodies and immunoproteins within one analytical run; FDA-cleared bead-based systems can simultaneously detect multiple disease-specific IgG antibodies, reducing the need for separate assays and repeated sample handling. The result is a more efficient Immunoprotein Diagnostic Testing Market where multiplex diagnostics, antibody profiling, and automated immunoassay platforms support higher-throughput laboratory testing.
02 Mass Spectrometry Moving into Immunoglobulin Testing Conventional immunoassays can face limitations when laboratories need more detailed characterization of monoclonal proteins and closely related immunoglobulin patterns. Mass spectrometry is therefore moving deeper into immunoprotein testing, with FDA-classified systems supporting analysis of immunoglobulin classes including IgG, IgA, IgM, IgD, and IgE as well as monoclonal protein characterization. The result is a more precise Immunoprotein Diagnostic Testing Market where protein diagnostics, monoclonal immunoglobulin analysis, and advanced laboratory testing provide more detailed information for complex clinical evaluation.
September 2025 Danaher expanded its diagnostic technologies portfolio through advancements in immunoassay platforms and clinical testing solutions. The company focused on improving disease monitoring, biomarker analysis, and laboratory efficiency.
July 2025 Siemens Healthineers expanded its immunoprotein diagnostic solutions by advancing automated laboratory systems and immunoassay technologies. The developments focused on improving diagnostic workflows and supporting personalized healthcare.
June 2025 Roche Diagnostics expanded its immunodiagnostics portfolio by enhancing electrochemiluminescence-based testing solutions for clinical applications. The company focused on improving biomarker detection, diagnostic precision, and laboratory automation.
May 2025 Abbott expanded its immunoprotein diagnostic testing portfolio by advancing automated immunoassay platforms and laboratory diagnostic solutions. The developments focused on improving testing accuracy, workflow efficiency, and disease detection capabilities.